Zhang Yaqin, Zhang Baolin
Division of Therapeutic Proteins, Office of Biotechnology Products, Center for Drug Evaluation and Research, Food and Drug Administration, Bethesda, Maryland, USA.
Cancer Res. 2006 Jun 1;66(11):5592-8. doi: 10.1158/0008-5472.CAN-05-4004.
D4-GDI is a Rho GDP dissociation inhibitor that is widely expressed in hematopoietic cells. Its possible expression and function in breast cancer cells has not been described. Here, we found that D4-GDI is expressed in a panel of breast cancer cell lines, but not in benign-derived mammary epithelial cells. Knockdown of D4-GDI expression in MDA-MB-231 cells by RNA interference blocks cell motility and invasion. The cells lacking D4-GDI grown on Matrigel revert to a normal breast epithelial phenotype characterized by the formation of cavitary structures. Silencing D4-GDI expression inhibits beta1-integrin expression and cell-matrix adhesion. Reintroduction of D4-GDI fully restored both beta1-integrin expression and cellular invasion. Knockdown of D4-GDI in BT549 cells results in a similar effect. These results show that D4-GDI modulates breast cancer cell invasive activities.
D4-GDI是一种Rho GDP解离抑制剂,在造血细胞中广泛表达。其在乳腺癌细胞中的可能表达及功能尚未见报道。在此,我们发现D4-GDI在一组乳腺癌细胞系中表达,但在良性来源的乳腺上皮细胞中不表达。通过RNA干扰敲低MDA-MB-231细胞中D4-GDI的表达可阻断细胞迁移和侵袭。在基质胶上生长的缺乏D4-GDI的细胞恢复为以形成空泡状结构为特征的正常乳腺上皮表型。沉默D4-GDI表达可抑制β1整合素表达及细胞与基质的黏附。重新引入D4-GDI可完全恢复β1整合素表达及细胞侵袭能力。在BT549细胞中敲低D4-GDI也产生类似效果。这些结果表明D4-GDI可调节乳腺癌细胞的侵袭活性。